-
We Are A Specialty Care
Biopharma CompanyCommitted To Bringing Transformational Therapies
To Patients In China And Asia -
Fit For Purpose
We Transcend Clinical Application Insights That Drive Our
Clinical Development Strategy Through A Dual Wheel Model
Of Our Integrated Commercial Platform And Late Stage
Clinical Pipeline -
Specialty Care
BoutiqueWe Focus On Developing First-in-Class Innovative Pipeline
To Address Unmet Medical Needs In Respiratory For The
Vast Patient Community In Asia -
Asia Pac Vision
We Are Passionate About Exploring APAC Business Opportunities
And Have Substantive Progress In Our Asian Expansion Strategy
Bringing Therapies That Are More Accessible To People In China And Asia
Our Area Of Focus
We Have Developed A Differentiated Matrix Of Commercial Products And Innovative Pipeline Across Respiratory, Emergency Care, Iron Deficiency Anemia, Pain Management
Highlights
Founded by Mark Lotter in 2014, Nuance deploys the Dual Wheel model that develops a leading innovative pipeline, while maintaining a self-sustainable commercial operation in both China and Asia
-
5PRODUCTS
COMMERCIAL
-
5PIPELINE
LATE STAGE CLINICAL
-
500+
EMPLOYEES WORLDWIDE
Our Transformative Journey
-
2022
Licensed in First-in-Class MVA-BN-RSV Vaccine from Bavarian Nordic
Licensed in allergy alleviation / virus prevention nasal spray Bentrio™ from Altamira Therapeutics
-
2021
Licensed in First-in-Class COPD dual MOA PDE 3&4 inhibitor Ensifentrine from Verona Pharma
Licensed in neonatal RDS drug / device combo Aerofact™ from Aerogen Pharma
Acquired Sino Health with access to 3 emergency care products and a GSP license in Zhuhai
-
2020
Licensed in post-operative pain product Ketorolac (NTM-001) from Neumentum
Raised US$ 181 million Series D equity funding
-
-
2018
Established partnership with Aerogen Pharma on nebulizer device
Accumulatively raised US$ 80 million equity funding
-
-
2022
2021
2020
2019
2018
2015
2014
-
2022
-
2021
-
2020
-
2019
-
2018
-
2015
-
2014
Latest News
-
2022-11-13
IND Approval for Respiratory Syncytial Virus (RSV) Vaccine in China
SHANGHAI, Nov. 13, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application supporting its pivotal phase III clinical tr
-
2022-10-28
专访优锐医药：呼吸精品特药领域，如何打造现金“造血”教科书？
近日，动脉新医药访谈了优锐医药创始人兼CEO Mark Lotter先生。Mark Lotter曾是阿斯利康的首批来华高管，拥有超过20年的中国医疗行业市场经验。Mark Lotter与我们分享了优锐医药如何练就现金“造血”能力，并逐步成长为具有差异化的特药医疗公司。
-
2022-08-18
IND Approval for Ensifentrine Pivotal Clinical Trials for COPD in China
SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application supporting its pivotal clinical trial of Ens
CONTACT
Suite 639, East Tower, No 1376 Nan Jing West Road, Shanghai. 200040
Copyright 2022 NUANCE BIOTECH INC reserved. 沪ICP备17029781号-4